Nykode Therapeutics (5VB) Stock Overview

A clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. More details

5VB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	2/6

Risk Analysis

Earnings are forecast to decline by an average of 23.3% per year for the next 3 years

Dividend of 28.99% is not well covered by earnings or free cash flows

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue ($453K)

+ 1 more risk

5VB Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

4.1k

US$21.53

67.7% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Nykode Therapeutics AS Competitors

Price History & Performance

Summary of share price highs, lows and changes for Nykode Therapeutics
Historical stock prices
Current Share Price	NOK 0.25
52 Week High	NOK 0.30
52 Week Low	NOK 0.086
Beta	1.17
1 Month Change	21.48%
3 Month Change	41.08%
1 Year Change	88.11%
3 Year Change	-87.88%
5 Year Change	n/a
Change since IPO	-96.56%

Recent updates

Shareholder Returns

	5VB	DE Biotechs	DE Market
7D	11.1%	-1.8%	-5.2%
1Y	88.1%	1.4%	-1.6%

Return vs Industry: 5VB exceeded the German Biotechs industry which returned 1.4% over the past year.

Return vs Market: 5VB exceeded the German Market which returned -1.6% over the past year.

Price Volatility

Is 5VB's price volatile compared to industry and market?
5VB volatility
5VB Average Weekly Movement	19.4%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in DE Market	14.4%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: 5VB's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 5VB's weekly volatility has decreased from 43% to 19% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2006	59	Michael Engsig	nykode.com

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10

Nykode Therapeutics AS Fundamentals Summary

How do Nykode Therapeutics's earnings and revenue compare to its market cap?
5VB fundamental statistics
Market cap	€92.83m
Earnings (TTM)	-€10.54m
Revenue (TTM)	€390.03k

238.0x

P/S Ratio

-8.8x

P/E Ratio

Is 5VB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
5VB income statement (TTM)
Revenue	US$453.00k
Cost of Revenue	US$0
Gross Profit	US$453.00k
Other Expenses	US$12.69m
Earnings	-US$12.24m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Apr 17, 2026

Earnings per share (EPS)	-0.037
Gross Margin	100.00%
Net Profit Margin	-2,701.99%
Debt/Equity Ratio	0%

How did 5VB perform over the long term?

See historical performance and comparison

Dividends

29.0%

Current Dividend Yield

-241%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/10 02:34
End of Day Share Price	2026/03/10 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nykode Therapeutics AS is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Viktor Sundberg	ABG Sundal Collier Sponsored
Geir Holom	DNB Carnegie
Lucy Codrington	Jefferies LLC

Nykode Therapeutics ASDB:5VB Stock Report